Share Prices & Company Research

Market News

03 Jun 2019 | 15:06

Avacta to submit clinical trial application in early 2020

Biotherapeutics and research reagent developer Avacta Group said that it was planning to submit an application early in 2020 to conduct a clinical study in patients with selected solid tumours.

Avacta's tumour microenvironment activated drug conjugates, or TMAC, were a ground-breaking new form of cancer immunotherapy, co-invented with Tufts University Medical School, the company said.

Avacta said that it was now in a position to test a TMAC linker in humans, a major de-risking milestone for its TMAC programme, well ahead of its original plans.

'What is so attractive about Avacta's Affimer TMAC programme is that it offers a way to combine chemotherapy with immune checkpoint inhibitors without exposing the whole body to the same level of the chemo-toxin,' chief executive Alastair Smith said.

'Whilst immunotherapies offer great promise for cancer patients, it is well established that only a relatively small sub-group of patients see durable responses to single immune checkpoint therapies.'

'Avacta is directly addressing this urgent clinical need with its novel Affimer TMAC and bispecific programmes.'

At 3:06pm: (LON:AVCT) Avacta Group PLC share price was +2p at 31.75p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.